ArticleBMC complementary medicine and therapies2025
Interaction between rasagiline and Pueraria radix in in vitro models of parkinson's disease.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe management of Parkinson's disease (PD) remains challenging owing to the limitations of current therapies. Although rasagiline (RASA), a monoamine oxidase-B (MAO-B) inhibitor, offers advantages over levodopa, its efficacy as a monotherapy is moderate. Pueraria root (PR), a traditional East Asian medicine, has demonstrated neuroprotective potential against several neurodegenerative conditions. This study investigated the pharmacodynamic and pharmacokinetic interactions between RASA and PR to evaluate their potential as a combination therapy for PD.
methodsWe examined synergistic effects on MAO-B inhibition by performing MAO-B enzyme reaction assay. We measured the cell viability for evaluating the neuroprotective effects of their co-administration against 6-OHDA-induced toxicity in PC12 cells. For investigating the interaction of drug metabolism, CYP450 expressions were measured in hepatocytes using quantitative real-time polymerase chain reaction.
resultsConcentration-dependent studies revealed a significant synergistic inhibition of MAO-B activity when RASA and PR were co-administered at specific ratios, as confirmed by combination index analysis. Although neither of the two drugs alone provided significant neuroprotection at concentrations effective for MAO-B inhibition, their co-administration significantly increased the survival of in 6-OHDA-treated cells. Importantly, investigation of CYP450 metabolism demonstrated minimal interference between these compounds, with no significant alterations in the expression patterns of relevant CYP isoforms during co-administration.
conclusionThese findings suggest that the RASA - PR combination offers enhanced therapeutic potential through synergistic effects, while maintaining favourable metabolic compatibility. This study establishes a scientific foundation for integrating traditional herbal medicine with conventional pharmaceuticals in PD management, potentially allowing for reduced conventional drug dosages while improving therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.